Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Staszewski

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|May 1, 1995
A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial GroupH Jablonowski, K Arasteh, S Staszewski, et al.
The Journal of Infection|July 6, 2010
Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65RC Stephan, B Dauer, M Bickel, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1988
HIV infection and distribution of GC alleles in AIDS patients, i.v. drug addicts, and hemophiliacsP Kühnl, S Seidl, G Holzberger, et al.
AIDS (London, England)|December 2, 1998
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjectsS Staszewski, C Katlama, T Harrer, et al.
The Journal of Infectious Diseases|November 6, 2004
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study groupA Mocroft, B Ledergerber, J P Viard, et al.
HIV Medicine|September 1, 2007
A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophyM Bickel, J Eisen, C Stephan, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
The Journal of Infectious Diseases|May 1, 1995
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitorS Staszewski, F E Massari, A Kober, et al.
JAMA|July 10, 1996
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working GroupS Staszewski, C Loveday, J J Picazo, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|May 1, 1995
A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial GroupH Jablonowski, K Arasteh, S Staszewski, et al.
The Journal of Infection|July 6, 2010
Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65RC Stephan, B Dauer, M Bickel, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1988
HIV infection and distribution of GC alleles in AIDS patients, i.v. drug addicts, and hemophiliacsP Kühnl, S Seidl, G Holzberger, et al.
AIDS (London, England)|December 2, 1998
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjectsS Staszewski, C Katlama, T Harrer, et al.
The Journal of Infectious Diseases|November 6, 2004
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study groupA Mocroft, B Ledergerber, J P Viard, et al.
HIV Medicine|September 1, 2007
A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophyM Bickel, J Eisen, C Stephan, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
The Journal of Infectious Diseases|May 1, 1995
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitorS Staszewski, F E Massari, A Kober, et al.
JAMA|July 10, 1996
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working GroupS Staszewski, C Loveday, J J Picazo, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 10